British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005.
Smith
C H
CH
St John's Institute of Dermatology, GKT School of Medicine, St Thomas' Hospital, London SE1 7EH, UK. Catherine.smith@kcl.ac.uk
Anstey
A V
AV
Barker
J N W N
JN
Burden
A D
AD
Chalmers
R J G
RJ
Chandler
D
D
Finlay
A Y
AY
Griffiths
C E M
CE
Grifitths
C E M
CE
Jackson
K
K
McHugh
N J
NJ
McKenna
K E
KE
Reynolds
N J
NJ
Ormerod
A D
AD
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018845:CD11 Antigens / Q000276:immunology; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D018579:Patient Selection; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012074:Remission Induction; D012306:Risk; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018845:CD11 Antigens; D007074:Immunoglobulin G; D007155:Immunologic Factors; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept; C472181:efalizumab